OncoMatch/Clinical Trials/NCT06756152
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Is NCT06756152 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 for biphenotypic acute leukemia.
Treatment: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 — GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Demographics
Lab requirements
Kidney function
clearance of endogenous creatinine ≥ 70 ml / min
Liver function
total bilirubin, ALT, AST, ALP ≤ 2 norms
Cardiac function
left ventricular ejection fraction ≥ 40% according to ultrasound of the heart
Heart function: left ventricular ejection fraction <40% according to ultrasound of the heart; Kidney function: clearance of endogenous creatinine < 70 ml / min; Liver function: total bilirubin, ALT, AST, ALP > 2 norms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06756152 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify